Molecular Formula | C27H28N4O5 |
Molar Mass | 488.54 |
Density | 1.34 |
Melting Point | 175 - 180°C |
Boling Point | 758.7±60.0 °C(Predicted) |
Solubility | Chloroform (Slightly), Methanol (Slightly) |
Vapor Presure | 0.001Pa at 25℃ |
Appearance | Solid |
Color | White to Pale Beige |
pKa | 0.78±0.20(Predicted) |
Storage Condition | Sealed in dry,Room Temperature |
Use | This product is for scientific research only and shall not be used for other purposes. |
LogP | 172 at 22.8℃ |
introduction | 1-(4-methoxyphenyl) -7-oxo-6-[4-(2-oxopiperidine-1-yl) phenyl]-4,5,6, 7-tetrahydro-1H-pyrazolo [3,4-C] Pyridine-3-carboxylic acid ethyl ester is an intermediate for the preparation of apixaban. apixaban is an antithrombotic drug. It is a direct inhibitor of factor Xa jointly developed by Bristol-Myers Squibb and Pfizer. It was approved for listing in the European Union in March 2011, and F DA approved the drug for listing in the United States in December 2012. |
Use | 1-(4-methoxyphenyl) -7-oxo-6-[4-(2-oxopiperidine-1-yl) phenyl]-4,5,6, 7-tetrahydro-1H-pyrazolo [3, ethyl 4-C] pyridine-3-carboxylate is used in the synthesis and preparation of the drug Ridecivir apisaban. |